Avacopan May Be Effective Option to Steroids for AAV, Phase 3 Trial Finds

Avacopan May Be Effective Option to Steroids for AAV, Phase 3 Trial Finds

287491

Avacopan May Be Effective Option to Steroids for AAV, Phase 3 Trial Finds

Use of avacopan can increase remission rates and improve kidney function in people with ANCA-associated vasculitis (AAV), while limiting the toxicity associated with standard steroid therapy, according to results from a Phase 3 clinical trial. Top-line data from the ADVOCATE trial, which opened on March 15, 2017, and concluded on Nov. 1, 2019, were announced by the company shortly after it ended. Now, its findings have undergone a peer review and are presented in the study “Avacopan for the…

You must be logged in to read/download the full post.